NEO Neogenomics Inc

Price (delayed)

$44.45

Market cap

$5.46B

P/E Ratio

72.87

Dividend/share

N/A

EPS

$0.61

Enterprise value

$5.68B

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
The equity has soared by 76% year-on-year and by 36% since the previous quarter
The revenue rose by 21% YoY and by 8% QoQ
The quick ratio has contracted by 49% from the previous quarter but it has grown by 10% YoY
The gross margin has grown by 6% from the previous quarter but it has contracted by 2.5% YoY
NEO's debt has soared by 168% YoY

Key stats

What are the main financial stats of NEO
Market
Shares outstanding
122.82M
Market cap
$5.46B
Enterprise value
$5.68B
Valuations
Price to earnings (P/E)
72.87
Price to book (P/B)
4.56
Price to sales (P/S)
10.76
EV/EBIT
82.52
EV/EBITDA
50.22
EV/Sales
11.62
Earnings
Revenue
$488.7M
EBIT
$68.82M
EBITDA
$113.09M
Free cash flow
-$49.21M
Per share
EPS
$0.61
Free cash flow per share
-$0.42
Book value per share
$9.74
Revenue per share
$4.13
TBVPS
$7.82
Balance sheet
Total assets
$1.9B
Total liabilities
$747.95M
Debt
$588.7M
Equity
$1.15B
Working capital
$622.66M
Liquidity
Debt to equity
0.51
Current ratio
7.28
Quick ratio
6.84
Net debt/EBITDA
1.94
Margins
EBITDA margin
23.1%
Gross margin
42.2%
Net margin
14.7%
Operating margin
-5.6%
Efficiency
Return on assets
5.4%
Return on equity
8.6%
Return on invested capital
8.5%
Return on capital employed
3.8%
Return on sales
14.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
-3.1%
1 week
0.02%
1 month
-5.3%
1 year
7.76%
YTD
-17.44%
QTD
-7.86%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$488.7M
Gross profit
$206.08M
Operating income
-$27.27M
Net income
$71.73M
Gross margin
42.2%
Net margin
14.7%
The company's operating income fell by 50% YoY and by 15% QoQ
Neogenomics's operating margin has decreased by 24% YoY and by 8% from the previous quarter
The revenue rose by 21% YoY and by 8% QoQ
Neogenomics's gross profit has increased by 18% YoY and by 14% QoQ

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
P/E
72.87
P/B
4.56
P/S
10.76
EV/EBIT
82.52
EV/EBITDA
50.22
EV/Sales
11.62
The equity has soared by 76% year-on-year and by 36% since the previous quarter
The price to book (P/B) is 30% less than the last 4 quarters average of 6.5 and 11% less than the 5-year quarterly average of 5.1
The price to sales (P/S) is 74% higher than the 5-year quarterly average of 6.2 but 6% lower than the last 4 quarters average of 11.5
The revenue rose by 21% YoY and by 8% QoQ

Efficiency

How efficient is Neogenomics business performance

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 154% greater than the total liabilities
Neogenomics's total liabilities has soared by 157% YoY and by 15% from the previous quarter
The total assets has soared by 101% year-on-year and by 27% since the previous quarter
NEO's debt is 49% lower than its equity
NEO's debt has soared by 168% YoY
The equity has soared by 76% year-on-year and by 36% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.